FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:1318-1320 October 24, 1996 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Packer, M. PubMed Citation

To the Editor: In their collection of studies evaluating the efficacy of carvedilol in congestive heart failure (May 23 issue),¹ Packer et al. replaced the analyses of primary end points with an analysis of mortality. The data in the article come from four different studies, none of which used overall mortality as a prospective primary or secondary end point. The primary end points of the studies were measures of morbidity (exercise tolerance in three and hospitalization in the fourth). The analyses of these primary end points are not provided, analyses that were shown to have nonsignificant results (P>0.05) in three . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Moye, L. A (2008). Disciplined analyses in clinical trials: the dark heart of the matter. Stat Methods Med Res 17: 253-264 [Abstract]  
• Berger, V. W, Matthews, J R., Grosch, E. N (2008). On improving research methodology in clinical trials. Stat Methods Med Res 17: 231-242 [Abstract]  
• Moye, L. A. (2001). Random Research. Circulation 103: 3150-3153 [Abstract] [Full Text]  
• Abraham, W. T. (2000). {beta}-Blockers: The New Standard of Therapy for Mild Heart Failure. Arch Intern Med 160: 1237-1247 [Abstract] [Full Text]